314 related articles for article (PubMed ID: 33604757)
1. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.
Sanka RK; Eagle RC; Wojno TH; Neufeld KR; Grossniklaus HE
Ophthalmology; 2010 Feb; 117(2):343-51. PubMed ID: 19969358
[TBL] [Abstract][Full Text] [Related]
4. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
5. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma.
Tomaszewski MM; Lupton GP; Krishnan J; May DL
J Cutan Pathol; 1995 Aug; 22(4):310-8. PubMed ID: 7499570
[TBL] [Abstract][Full Text] [Related]
6. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
[TBL] [Abstract][Full Text] [Related]
7. SATB1 Defines a Subtype of Cutaneous CD30
Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
9. Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?
Cieza-Díaz DE; Prieto-Torres L; Rodríguez-Pinilla SM; Córdoba Mascuñano R; Manso Alonso R; Machan S; Piris Pinilla MÁ; Requena Caballero L
Am J Dermatopathol; 2019 Nov; 41(11):846-850. PubMed ID: 30946099
[TBL] [Abstract][Full Text] [Related]
10. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
[TBL] [Abstract][Full Text] [Related]
11. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L.
Sigel JE; Hsi ED
Mod Pathol; 2000 Apr; 13(4):446-51. PubMed ID: 10786813
[TBL] [Abstract][Full Text] [Related]
13. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
14. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of CD30-positive anaplastic large cell lymphoma and mycosis fungoides.
Kang SK; Chang SE; Choi JH; Sung KJ; Moon KC; Koh JK
Clin Exp Dermatol; 2002 May; 27(3):212-5. PubMed ID: 12072011
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
17. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
18. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
19. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous anaplastic large cell lymphoma.
Brown RA; Fernandez-Pol S; Kim J
J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
